MAPT and osteoporosis: Significantly higher p-Tau Ser422 levels were observed in bone tissues from osteoporosis patients than those from healthy individuals (Fig. 7p, q), highlighting that a therapeutic drug, such as TRx0237, that targets/inhibits p-Tau Ser422, might prevent bone loss in general in addition to GIO in clinic.